JP2004520264A - 鉄錯化蛋白質および一酸化窒素代謝の前駆体および／または一酸化窒素の化学的ドナーを含有する組成物ならびにその使用 - Google Patents
鉄錯化蛋白質および一酸化窒素代謝の前駆体および／または一酸化窒素の化学的ドナーを含有する組成物ならびにその使用 Download PDFInfo
- Publication number
- JP2004520264A JP2004520264A JP2002515293A JP2002515293A JP2004520264A JP 2004520264 A JP2004520264 A JP 2004520264A JP 2002515293 A JP2002515293 A JP 2002515293A JP 2002515293 A JP2002515293 A JP 2002515293A JP 2004520264 A JP2004520264 A JP 2004520264A
- Authority
- JP
- Japan
- Prior art keywords
- iron
- pharmaceutical composition
- nitric oxide
- food supplement
- supplement according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims abstract description 104
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 35
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 35
- 230000004060 metabolic process Effects 0.000 title claims abstract description 26
- 239000002243 precursor Substances 0.000 title claims abstract description 26
- 239000000126 substance Substances 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 46
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 41
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical class [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 claims abstract description 10
- 208000007502 anemia Diseases 0.000 claims abstract description 8
- 206010003549 asthenia Diseases 0.000 claims abstract description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 135
- 229910052742 iron Inorganic materials 0.000 claims description 66
- 235000018102 proteins Nutrition 0.000 claims description 33
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 18
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 18
- 229930064664 L-arginine Natural products 0.000 claims description 16
- 235000014852 L-arginine Nutrition 0.000 claims description 16
- 102000010445 Lactoferrin Human genes 0.000 claims description 16
- 108010063045 Lactoferrin Proteins 0.000 claims description 16
- 150000002505 iron Chemical class 0.000 claims description 16
- 235000021242 lactoferrin Nutrition 0.000 claims description 16
- 229940078795 lactoferrin Drugs 0.000 claims description 16
- 241000283690 Bos taurus Species 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical group CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004338 Transferrin Human genes 0.000 claims description 3
- 108090000901 Transferrin Proteins 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 239000012581 transferrin Substances 0.000 claims description 3
- SUUWYOYAXFUOLX-ZBRNBAAYSA-N (2s)-2-aminobutanedioic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N SUUWYOYAXFUOLX-ZBRNBAAYSA-N 0.000 claims description 2
- IMWCPTKSESEZCL-SPSNFJOYSA-H (e)-but-2-enedioate;iron(3+) Chemical compound [Fe+3].[Fe+3].[O-]C(=O)\C=C\C([O-])=O.[O-]C(=O)\C=C\C([O-])=O.[O-]C(=O)\C=C\C([O-])=O IMWCPTKSESEZCL-SPSNFJOYSA-H 0.000 claims description 2
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical group Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims description 2
- RVEWUBJVAHOGKA-WOYAITHZSA-N Arginine glutamate Chemical compound OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N RVEWUBJVAHOGKA-WOYAITHZSA-N 0.000 claims description 2
- 241000283707 Capra Species 0.000 claims description 2
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical group [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 2
- 241000219745 Lupinus Species 0.000 claims description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 2
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 2
- 102100029469 WD repeat and HMG-box DNA-binding protein 1 Human genes 0.000 claims description 2
- 101710097421 WD repeat and HMG-box DNA-binding protein 1 Proteins 0.000 claims description 2
- 229940072107 ascorbate Drugs 0.000 claims description 2
- MDXRFOWKIZPNTA-UHFFFAOYSA-L butanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)CCC([O-])=O MDXRFOWKIZPNTA-UHFFFAOYSA-L 0.000 claims description 2
- VEPSWGHMGZQCIN-UHFFFAOYSA-H ferric oxalate Chemical compound [Fe+3].[Fe+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O VEPSWGHMGZQCIN-UHFFFAOYSA-H 0.000 claims description 2
- PVFSDGKDKFSOTB-UHFFFAOYSA-K iron(3+);triacetate Chemical compound [Fe+3].CC([O-])=O.CC([O-])=O.CC([O-])=O PVFSDGKDKFSOTB-UHFFFAOYSA-K 0.000 claims description 2
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims description 2
- 150000008535 L-arginines Chemical class 0.000 claims 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000008139 complexing agent Substances 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 13
- 238000004113 cell culture Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 6
- 206010022971 Iron Deficiencies Diseases 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 2
- 206010061958 Food Intolerance Diseases 0.000 description 2
- 206010016946 Food allergy Diseases 0.000 description 2
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000020932 food allergy Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 159000000014 iron salts Chemical class 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0009883A FR2812200B1 (fr) | 2000-07-27 | 2000-07-27 | Composition contenant une proteine complexant le fer et un precurseur du metabolisme du monoxyde d'azote et/ou un donneur chimique de monoxyde d'azote ; et utilisations |
| PCT/FR2001/002469 WO2002009740A1 (fr) | 2000-07-27 | 2001-07-27 | Composition contenant une proteine complexant le fer et un precurseur du metabolisme du monoxyde d'azote et/ou un donneur chimique de monoxyde d'azote et utilisations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004520264A true JP2004520264A (ja) | 2004-07-08 |
| JP2004520264A5 JP2004520264A5 (https=) | 2005-03-03 |
Family
ID=8852998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002515293A Pending JP2004520264A (ja) | 2000-07-27 | 2001-07-27 | 鉄錯化蛋白質および一酸化窒素代謝の前駆体および／または一酸化窒素の化学的ドナーを含有する組成物ならびにその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6984624B2 (https=) |
| EP (1) | EP1303296B1 (https=) |
| JP (1) | JP2004520264A (https=) |
| AT (1) | ATE292978T1 (https=) |
| AU (1) | AU2001279922A1 (https=) |
| DE (1) | DE60110084D1 (https=) |
| FR (1) | FR2812200B1 (https=) |
| WO (1) | WO2002009740A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009101789A1 (ja) * | 2008-02-14 | 2009-08-20 | Morinaga Milk Industry Co., Ltd. | 卵巣機能改善剤 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10215315A1 (de) * | 2002-04-05 | 2003-11-20 | Aventis Behring Gmbh Intellect | Human-Transferrin zur Behandlung der Anaemia of Chronic Disease (ACD) und des funktionellen Eisenmangels |
| US8126524B2 (en) | 2003-09-12 | 2012-02-28 | Or-Nim Medical Ltd. | Method and apparatus for noninvasively monitoring parameters of a region of interest in a human body |
| EP1589283B1 (en) * | 2004-04-23 | 2006-08-16 | Abb Research Ltd. | Model and control of a waste combustion process |
| RU2007117147A (ru) * | 2004-10-08 | 2008-11-20 | Юнилевер Н.В. (Nl) | Комплекс железа |
| EP1867330A4 (en) * | 2005-03-30 | 2012-01-25 | Kyowa Hakko Bio Co Ltd | METHOD FOR IMPROVING THE STORAGE STABILITY OF A SUBSTANCE |
| WO2009102677A1 (en) * | 2008-02-11 | 2009-08-20 | Tabatchnick Fine Foods, Inc. | A nutritionally enhanced therapeutic preventative food supplement and method of making same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09508097A (ja) * | 1993-11-02 | 1997-08-19 | アメリカ合衆国 | 虚血再灌流傷害における保護剤としての酸化窒素放出化合物の使用 |
| US5827729A (en) * | 1996-04-23 | 1998-10-27 | Advanced Tissue Sciences | Diffusion gradient bioreactor and extracorporeal liver device using a three-dimensional liver tissue |
| US6333311B1 (en) * | 1997-02-03 | 2001-12-25 | Pharming | Useful properties of human lactoferrin and variants thereof |
-
2000
- 2000-07-27 FR FR0009883A patent/FR2812200B1/fr not_active Expired - Fee Related
-
2001
- 2001-07-27 WO PCT/FR2001/002469 patent/WO2002009740A1/fr not_active Ceased
- 2001-07-27 DE DE60110084T patent/DE60110084D1/de not_active Expired - Lifetime
- 2001-07-27 AT AT01958190T patent/ATE292978T1/de not_active IP Right Cessation
- 2001-07-27 EP EP01958190A patent/EP1303296B1/fr not_active Expired - Lifetime
- 2001-07-27 AU AU2001279922A patent/AU2001279922A1/en not_active Abandoned
- 2001-07-27 JP JP2002515293A patent/JP2004520264A/ja active Pending
- 2001-07-27 US US10/333,554 patent/US6984624B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009101789A1 (ja) * | 2008-02-14 | 2009-08-20 | Morinaga Milk Industry Co., Ltd. | 卵巣機能改善剤 |
| JP5022454B2 (ja) * | 2008-02-14 | 2012-09-12 | 森永乳業株式会社 | 卵巣機能改善剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE292978T1 (de) | 2005-04-15 |
| EP1303296B1 (fr) | 2005-04-13 |
| WO2002009740A1 (fr) | 2002-02-07 |
| DE60110084D1 (de) | 2005-05-19 |
| FR2812200B1 (fr) | 2003-01-03 |
| FR2812200A1 (fr) | 2002-02-01 |
| US6984624B2 (en) | 2006-01-10 |
| US20040033945A1 (en) | 2004-02-19 |
| EP1303296A1 (fr) | 2003-04-23 |
| AU2001279922A1 (en) | 2002-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8021659B2 (en) | Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof | |
| EP0339656B1 (en) | Undenatured whey protein concentrate | |
| Ianiro et al. | Lactoferrin: From the structure to the functional orchestration of iron homeostasis | |
| CN101212961A (zh) | 羟甲基丁酸盐组合物及其应用 | |
| JP4327607B2 (ja) | ラクトフェリン | |
| Mok et al. | Oral glutamine and amino acid supplementation inhibit whole-body protein degradation in children with Duchenne muscular dystrophy | |
| ES2256070T3 (es) | Actividad antimicrobiana de la primera agrupacion cationica de lactoferrina humana. | |
| AU2015373326B2 (en) | Use of probiotics to increase male fertility | |
| WO2011150395A2 (en) | Nutrient compositions | |
| JP2004520264A (ja) | 鉄錯化蛋白質および一酸化窒素代謝の前駆体および／または一酸化窒素の化学的ドナーを含有する組成物ならびにその使用 | |
| EP1817006B1 (en) | Liposomal formulation for oral administration of glutathione (reduced) | |
| WO2006105155A2 (en) | Administration of glutathione (reduced) via intravenous or encapsulated in liposome for treatment of tnf-alpha effects and elu-like viral symptoms | |
| Ono et al. | Hypervitaminosis A: a contributing factor to anemia in regular dialysis patients | |
| RU2760674C1 (ru) | Применение препаратов растения polyscias filicifolia или его фрагментов для лечения элементозов и их последствий | |
| EP2234611B1 (en) | Composition for treating sterile inflammation | |
| US20150174218A1 (en) | ANGIOGENIN COMPLEXES (ANGex) WITH ANABOLIC HORMONES FOR IMPROVING BONE HEALTH | |
| RU2372899C2 (ru) | Фармацевтическая композиция для лечения псориаза, содержащая l-серин, l-изолейцин, фолиевую кислоту и микроэлементы | |
| Elgar | N-acetylcysteine: A Review of Clinical Use and Efficacy | |
| US7060677B1 (en) | Antimicrobial activity of the first cationic cluster of human lactoferrin | |
| WO2012038590A1 (en) | Improved dietary substitution for treating or preventing cancer | |
| TW202612716A (zh) | 促進幹細胞增生之食品組合物及其製備方法 | |
| JP2022186084A (ja) | グルタチオン産生増強剤 | |
| Yaacob et al. | LACTIC ACID BACTERIA IS BENEFICIAL FOR ORAL APHTHOUS ULCERATIONS-A PRELIMINARY REPORT | |
| Fisher | Nutrition and gastrointestinal diseases | |
| Cuisset et al. | 1. E. Mok, C. Eléouet-Da Violante, C. Daubrosse, F. Gottrand, O. Rigal, JE. Fontan, J |